-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, E8RN3JAQdK+0BQQKOt93HEK+g2/SOLt4Z4G0Kr6CZSNF9lXpL67qvJkoh/ONWJMC an0uELqkGnmuBqSFhsjjFg== 0000950123-03-012230.txt : 20031106 0000950123-03-012230.hdr.sgml : 20031106 20031106115902 ACCESSION NUMBER: 0000950123-03-012230 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20031106 GROUP MEMBERS: BAYER BETEILIGUNGSVERWALTUNGSGESELLSCHAFT MBH SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MILLENNIUM PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001002637 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043177038 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-49167 FILM NUMBER: 03981454 BUSINESS ADDRESS: STREET 1: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6176797000 MAIL ADDRESS: STREET 1: 75 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BAYER AKTIENGESELLSCHAFT CENTRAL INDEX KEY: 0001144145 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: BAYERWERK, GEBAEUDE W1 STREET 2: KAISER-WILHELM-ALLEE CITY: LEVERKUSEN GERMANY STATE: I8 ZIP: D-51368 BUSINESS PHONE: 492143081933 MAIL ADDRESS: STREET 1: BAYERWERK, GEBAEUDE W1 STREET 2: KAISER-WILHELM-ALLEE CITY: LEVERKUSEN GERMANY STATE: I8 ZIP: D-51368 SC 13D/A 1 y91416a2sc13dza.txt AMENDMENT #2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Millennium Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 0005999021 (CUSIP Number) Gregory Malobocki, Esq. Bayer Corporation 63 North Street Medfield, MA 02052-1688 with a copy to: Knute J. Salhus, Esq. Wilmer, Cutler & Pickering 399 Park Avenue New York, NY 10022 (Name, Address and Telephone Number of Person Authorized to ----------------------------------------------------------- Receive Notices and Communications) ---------------------------------- October 28, 2003 ---------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of [section] 240.13d-1(e), 240.13d-1(f), or 240.13d-1(g), check the following box. [ ] Note: Schedules filed in paper format shall include a signed original and five copies of this Schedule, including all exhibits. See Rule 240.13d-7 for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Page 2 of 5 Pages CUSIP NO. 0005999021 --------------------- ---------------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS Bayer AG ---------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X] (b) [ ] ---------------------------------------------------------------------------- 3. SEC USE ONLY ---------------------------------------------------------------------------- 4. SOURCE OF FUNDS ---------------------------------------------------------------------------- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] ---------------------------------------------------------------------------- 6. CITIZENSHIP OR PLACE OF ORGANIZATION Federal Republic of Germany ----------------------------------------------------------------------------- 7. SOLE VOTING POWER NUMBER OF 0 SHARES -------------------------------------------------------- BENEFICIALLY 8. SHARED VOTING POWER OWNED BY 0 EACH -------------------------------------------------------- REPORTING 9. SOLE DISPOSITIVE POWER PERSON WITH 0 -------------------------------------------------------- 10. SHARED DISPOSITIVE POWER 0 ----------------------------------------------------------------------------- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 ----------------------------------------------------------------------------- 12. CHECK BOX IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES SHARES [ ] ----------------------------------------------------------------------------- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ----------------------------------------------------------------------------- 14. TYPE OF REPORTING PERSON CO ----------------------------------------------------------------------------- Page 3 of 5 Pages CUSIP NO. 0005999021 --------------------- ---------------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON Bayer Beteiligungsverwaltungsgesellschaft mbH ---------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [X] (b) [ ] ---------------------------------------------------------------------------- 3. SEC USE ONLY ---------------------------------------------------------------------------- 4. SOURCE OF FUNDS ---------------------------------------------------------------------------- 5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] ---------------------------------------------------------------------------- 6. CITIZENSHIP OR PLACE OF ORGANIZATION Federal Republic of Germany ----------------------------------------------------------------------------- 7. SOLE VOTING POWER NUMBER OF 0 SHARES -------------------------------------------------------- BENEFICIALLY 8. SHARED VOTING POWER OWNED BY 0 EACH -------------------------------------------------------- REPORTING 9. SOLE DISPOSITIVE POWER PERSON WITH 0 -------------------------------------------------------- 10. SHARED DISPOSITIVE POWER 0 ----------------------------------------------------------------------------- 11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 ----------------------------------------------------------------------------- 12. CHECK BOX IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] ----------------------------------------------------------------------------- 13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0% ----------------------------------------------------------------------------- 14. TYPE OF REPORTING PERSON CO ----------------------------------------------------------------------------- Page 4 of 5 Pages This Amendment No. 2 is filed by Bayer AG ("Bayer") and Bayer Beteiligungsverwaltungsgesellschaft mbH, formerly known as Agfa Holding GmbH, to amend and update the Schedule 13D filed on November 18, 1999 as amended July 6, 2000, relating to shares of common stock, $.001 par value per share (the "Common Stock"), of Millennium Pharmaceuticals, Inc., a Delaware corporation (the "Issuer"). All capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Schedule 13D, as amended. Items not included in this amendment are either not amended or are not applicable. Item 2. Identity and Background. On April 6, 2001, Agfa Holding GmbH changed its name to Bayer Beteiligungsverwaltungsgesellschaft mbH ("Agfa"). Information as to the executive officers and directors of Bayer is set forth in Exhibit A hereto and information as to the executive officers and directors of Agfa is set forth in Exhibit B hereto. During the past five years, neither Bayer or Agfa nor, to Bayer's knowledge, any of the persons listed in Exhibit A nor, to Agfa's knowledge, any of the persons listed in Exhibit B, has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors). During the past five years, neither Bayer or Agfa's nor, to Bayer's knowledge, any of the persons listed in Exhibit A nor, to Agfa's knowledge, any of the persons listed in Exhibit B, has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. Item 4. Purpose of Transaction. On October 28, 2003, Bayer and Agfa in the aggregate sold 19,830,640 shares of Common Stock to Credit Suisse First Boston, LLC ("Purchaser") in a private sale transaction for an aggregate sales price of $318,678,385. The shares of Common Stock sold constituted all of the shares of Common Stock previously owned by Bayer and Agfa. Item 5. Interest in Securities of the Issuer. (a), (b) Neither Bayer nor Agfa is the beneficial owner of any shares of Common Stock (0% of the outstanding shares of Common Stock). (c) On October 28, 2003, Bayer and Agfa sold 19,830,640 shares of Common Stock to Purchaser in a private sale transaction for an aggregate sales price of $318,678,385. (e) On October 28, 2003, Bayer and Agfa in the aggregate sold 19,830,640 shares of Common Stock to Purchaser in a private sale transaction for an aggregate sales price of $318,678,385. The shares of Common Stock sold constituted all of the shares of Common Stock previously owned by Bayer and Agfa. Thus, on October 28, 2003, Bayer and Agfa ceased to be the beneficial owners of more than five percent of shares of Common Stock. Item 7. Material to be Filed as Exhibits. Exhibit A Information concerning Bayer's executive officers and directors. Exhibit B Information concerning Agfa's executive officers and directors. Page 5 of 5 Pages Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this amendment to this statement is true and correct. Date: November 6, 2003 Bayer AG By: /s/ Klaus Kuehn ------------------------------- Klaus Kuehn Member, Board of Management By: /s/ Roland Hartwig ------------------------------- Dr. Roland Hartwig General Counsel Bayer Beteiligungsverwaltungsgesellschaft mbH By: /s/ Peter Mueller ------------------------------- Peter Mueller Managing Director EX-99.A 3 y91416a2exv99wa.txt INFO RE: EXECUTIVE OFFICERS AND DIRECTORS--BAYER Exhibit A --------- DIRECTORS AND EXECUTIVE OFFICERS OF BAYER AG The name, business address, and present principal occupation or employment of each of the directors and executive officers of Bayer AG are set forth below. Unless otherwise indicated, the business address of each such director or executive officer is Bayer Aktiengesellschaft, D-51368 Leverkusen, Federal Republic of Germany. All the directors and executive officers listed below are citizens of the Federal Republic of Germany, except for Mr. Kornblum, who is a U.S. citizen, Mr. Achleitner, who is a citizen of Austria and Mr. Ackermann, who is a citizen of Switzerland. Name and Business Address Present Principal Occupation or Employment - --------------------------------- ------------------------------------------- Werner Wenning.................. Chairman, Board of Management. Klaus Kuehn..................... Member, Board of Management. Dr. Udo Oels.................... Member, Board of Management. Richard Pott.................... Member, Board of Management. Dr. Manfred Schneider........... Chairman, Supervisory Board. Erhard Gipperich................ Vice Chairman, Supervisory Board; Chairman, Works Council. Dr. Paul Achleitner............. Member, Supervisory Board; Allianz AG Member of Board of Management, Allianz AG. Koniginstr. 28 80802 Munchen, Germany Dr. Josef Ackermann............. Member, Supervisory Board; Deutsche Bank AG Spokesman of the Board of Managing Directors Taunusanlage 12 and Chairman of the Group Executive Committee 60325 Frankfurt, Germany of Deutsche Bank AG. Karl-Josef Ellrich.............. Member, Supervisory Board; Chairman, Works Bayer AG, Dormagen Plant Council, Dormagen plant, Bayer AG. 41538 Dormagen, Germany Thomas Hellmuth................. Member, Supervisory Board; Bayer CropScience AG Agricultural Engineer, Langenfeld, Bayer AG. Elisabeth-Selbert-Str. 4a 40764 Langenfeld, Germany Prof. Dr. Ing. e.h. Hans-Olaf Henkel............... Member, Supervisory Board; Gottfried Wilhelm Leibniz e.V. President of Leibniz Association; Friedrichstr. 81 Vice President of the Federation of 10117 Berlin, Germany German Industry. Dr. h.c. Martin Kohlhaussen Member, Supervisory Board; Chairman of Commerzbank AG the Supervisory Board, Commerzbank AG. Kaiserplatz 60261 Frankfurt am Main, Germany John Christian Kornblum......... Member, Supervisory Board; Lazard & Co. GmbH Chairman of Bankhaus Lazard. Pariser Platz 4a 10117 Berlin, Germany Petra Kronen.................... Member, Supervisory Board; Bayer AG, Uerdingen Plant Chairman, Works Council, Uerdingen 47812 Krefeld, Germany plant, Bayer AG. Dr. Heinrich von Pierer......... Member, Supervisory Board; Siemens AG President and Chief Executive Officer, Wittelsbacherplatz 2 Siemens AG. 80333 Munchen, Germany Wolfgang Schenk................. Member, Supervisory Board; Graduate Engineer, Bayer AG. Hubertus Schmoldt............... Member, Supervisory Board; IG Bergbau, Chemie, Energie Chairman, German Mine, Chemical and Konigsworther Platz 6 Power Workers Union. 30167 Hannover, Germany Dieter Schulte........................ Member, Supervisory Board; German Trade Union Federation DGB Former Chairman of the German 10178 Berlin, Germany Unions Federation. Dipl.-Ing. Dr. Ing E.h. Jurgen Weber.. Member, Supervisory Board; Chairman of Deutsche Lufthansa AG the Management Board, Deutsche von Gablenz - Str. 2 - 6 Lufthansa AG. 50679 Koln, Germany Sigfried Wendlandt.................... Member, Supervisory Board; North Rhine IG Bergbau, Chemie, Energie District Secretary of the German Mine, Hans-Bockler - Str. 39 Chemical and Power Workers Union. 40476 Dusseldorf, Germany Reinhard Wendt........................ Member, Supervisory Board; Printer, Wolff Walsrode AG Walsrode, Bayer AG. 29655 Walsrode, Germany Thomas de Win......................... Member, Supervisory Board; Commercial Clerk, Pulheim, Bayer AG. Prof. Dr. Ernst-Ludwig Winnacker...... Member, Supervisory Board; Deutsche Forschungsgemeinschaft University Professor. Kennedyallee 40 53175 Bonn, Germany Dr. Hermann Wunderlich................ Member, Supervisory Board. Arndtstrasse 8 51519 Odenthal, Germany EX-99.B 4 y91416a2exv99wb.txt INFO RE: EXECUTIVE OFFICERS AND DIRECTORS--AGFA Exhibit B --------- DIRECTORS AND EXECUTIVE OFFICERS OF BAYER BETEILIGUNGSVERWALTUNGSGESELLSCHAFT MBH The name and present principal occupation or employment of each of the directors and executive officers of Bayer Beteiligungsverwaltungsgesellschaft mbH are set forth below. The business address of each such person is Bayer Aktiengesellschaft, D-51368 Leverkusen, Federal Republic of Germany. All such persons are citizens of the Federal Republic of Germany. Name Present Principal Occupation - --------------------------------- ------------------------------------ Peter Mueller.................... Managing Director; Head of Corporate Finance Department, Bayer AG. Klaus Kuehn...................... Managing Director; Chief Financial Officer, Bayer AG. -----END PRIVACY-ENHANCED MESSAGE-----